Practitioner Course

Long Covid Syndrome

Discover the latest on Long COVID Syndrome.
It's biology, mechanisms and treatment options.

Online Course
2 lessons


12 Months OR Subscriber Pass


60 min/lesson
2 hours total


Dr Heather Zwickey, Dr Jeff Novack and Dr Theoharis 

About this course

Covid-19 has been a triple hit for us. The virus is deadly, vaccinations have had consequences for some and we also have a strange and variable ongoing post-viral syndrome.

Post-Covid Syndrome, also known as Long Covid, is defined as symptoms that persist for more than three weeks after the diagnosis of Covid-19. Estimates suggest that up to a third of all people who contract Covid have some form of Post-Covid Syndrome, while around 80% of those that end up in hospital may be affected.

While our understanding of this syndrome is in its early phase, there are many aspects that we now understand and can make decisions around. This series of webinars are from two immunology experts each with a specific interest in this syndrome. They give as a clear vision of what the underlying pathophysiology of the syndrome is thought to be, and also, what we can do for our patients who are struggling with this new phenomenon.

Covid is a new challenge and Long Covid is another aspect that we appear to have good tool and strategies to address.
What you receive:
  • Clear protocol explanations from some of the world's top practitioners
  • Clinical pearls for improved practice results
  • Access to your audio and video recordings via the App Store
  • A downloadable PDF of the presenter’s slides
  • Links to all referenced research papers and useful clinical handouts
  • Access to the community hub where you can get answers to your questions
  • A 30-day money back guarantee

From this course you will

  • Learn how this virus creates a persistent inflammatory response that has a very slow resolution phase
  • Understand the impacts the infection has on the immune system and mitochondrial function
  • Discover the proposed mechanisms of cellular dysfunction
  • Learn why the inflammatory response to the virus fails to shut down appropriately
  • Have a new set of techniques that you can use to boost the effectiveness of practically all of the other therapies you are using
  • Discover how specific cytokine patterns manifest the symptom profiles seen in Long COVID
  • Understand the conditions that predict a poor response to this infection

What's in this course

Your Presenters

Dr Heather Zwickey PhD

Heather Zwickey is the Dean of Research and Graduate Studies at the National University of Natural Medicine and Director of the Helfgott Research Institute.

Heather has faculty appointments at Oregon Health and Science University and the University of Washington. She’s a leading researcher in the field of Integrative Medicine. She’s published more than 50 papers, spoken at more than 40 conferences, had several NIH grants, and won 8 leadership awards. Dr Zwickey has served on the National Vaccine Safety Working Group, the Scientific Advisory Board for the American Association for Naturopathic Physicians, the Scientific Advisory Board for the State of Oregon Retail Marijuana Sales.

Heather is the Dean of Research and Graduate Studies at the National University of Natural Medicine and Director of the Helfgott Research Institute. She also has faculty appointments at Oregon Health and Science University and the University of Washington. She’s a leading researcher in the field of Integrative Medicine.

Dr Jeff Novak

Dr Jeff Novak is currently on faculty as Associate Professor at Pacific Northwest University College of Medicine where he has taught pharmacology, immunology, infectious disease, and pathology at medical school level for 13 years.

He earned his PhD in pharmacology from the Department of Pharmacology at the University of Washington School of Medicine in signal transduction. Jeff did post-doctoral research in immunology and tyrosine kinase signaling at the Fred Hutchinson Cancer Center and research on T cell activation at the Virginia Mason Research Center. He has also done research on the effects of the mushroom extract PSK on immune function in mice and humans and is interested in the effect of natural products on the innate and adaptive immunity and on inflammation.

Theoharis C. Theoharides, BA, MS, MPhil, PhD, MD, FAAAAI

Dr Theoharides is Professor of Pharmacology and Internal Medicine, as well as Director of Molecular Immunopharmacology and Drug Discovery, in the Department of Immunology at Tufts University School of Medicine, Boston, MA, USA. He is also Adjunct Professor at the Institute of Neuro-Immune Medicine, Nova Southeastern University, Tampa, FL, USA, as well as Director of Health Science Programs and Research, American College of Greece, Athens, Greece.

He was born in Thessaloniki, Greece, and graduated with Honors from Anatolia College. He received all his degrees from Yale University (BA, cum laude in Biology and History of Medicine, MS, MPhil, PhD, MD), and was awarded the Dean’s Research Award and the Winternitz Price in Pathology. He trained in internal medicine at New England Medical Center, which awarded him the Oliver Smith Award “recognising excellence, compassion and service.” He also received a Certificate in Global Leadership from the Tufts Fletcher School of Law and Diplomacy and a Fellowship at the Harvard Kennedy School of Government. He has been serving as the Clinical Pharmacologist of the Massachusetts Drug Formulary Commission continuously since 1986.

In Greece, he served on the Supreme Advisory Health Councils of the Ministries of Health and of Social Welfare, as well as on the Board of Directors of the Institute of Pharmaceutical Research and Technology. He Chaired an International Committee appointed by the Hellenic Ministries of Education and Health for the establishment of an independent medical school in Greece, and he is a member of the International Advisory Committee for the University of Cyprus School of Medicine. He is also the Director of Health Science Programs and Research for the American College of Greece. He is a member of 15 academies and scientific societies. He was inducted into the Alpha Omega Alpha National Medical Honour Society and the Rare Diseases Hall of Fame. He has received the Tufts Excellence in Teaching ten times, the Tufts Distinguished Faculty Recognition Award twice, the Tufts Alumni Award for Faculty Excellence, and the Dr. George Papanicolaou Award.

He has also been awarded an Honorary Doctor of Medicine from Athens University and an Honorary Doctor of Sciences from Hellenic-American University, as well as the 2018 Albert Nelson Marquis Lifetime Achievement Award. Dr Theoharides is a member of the American Academy of Allergy, Asthma and Immunology. In 2020, he was inducted in the World Academy of Sciences. For his humanitarian efforts, he was honoured with Boston Mayor’s Community Award, the 2018 Distinguished Humanitarian Award (Marquis Who is Who), and he was recognised as “Archon” of the Ecumenical Patriarchate of Constantinople.

Dr Theoharides first showed that mast cells, known for causing allergic reactions, are critical for inflammation, especially in the brain, and are involved in a number of conditions that worsen with environmental triggers, especially mould, and stress such as allergies, asthma, autism spectrum disorder, eczema, fibromyalgia, interstitial cystitis/bladder pain syndrome, mast cell activation syndrome, migraines, multiple sclerosis, myalgic encephalomyelitis/ chronic fatigue syndrome, psoriasis and Long-COVID syndrome.

He has published over 480 scientific papers (in journals such as JBC, JACI, JPET, NEJM, Nature, PNAS, Science) with 40,276 citations (h-index 96) and 3 textbooks of pharmacology. He has been placed in the top 5% of authors most cited in pharmacological and immunological journals. He was instrumental in the development of ibuprofen (Motrin, with Upjohn), cetirizine (Zyrtec, with UCB) and slow-release niacin (Niaspan, with Abbott).